Nanoencapsulation of MDM2 inhibitor RG7388 and class-I HDAC inhibitor entinostat enhances their therapeutic potential through synergistic antitumor effects and reduction of systemic toxicity

Anas Abed, Michelle K Greene, Alhareth A Alsa'd, Andrea Lees, Andrew Hindley, Daniel B Longley, Simon S McDade, Christopher J Scott*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Downloads (Pure)

Abstract

Inhibitors of the p53-MDM2 interaction such as RG7388 have been developed to exploit latent tumor suppressive properties in p53 in 50% of tumors in which p53 is wild-type. However, these agents for the most part activate cell cycle arrest rather than death, and high doses in patients elicit on-target dose-limiting neutropenia. Recent work from our group indicates that combination of p53-MDM2 inhibitors with the class-I HDAC inhibitor Entinostat (which itself has dose-limiting toxicity issues) has the potential to significantly augment cell death in p53 wild-type colorectal cancer cells. We investigated whether coencapsulation of RG7388 and Entinostat within polymeric nanoparticles (NPs) could overcome efficacy and toxicity limitations of this drug combination. Combinations of RG7388 and Entinostat across a range of different molar ratios resulted in synergistic increases in cell death when delivered in both free drug and nanoencapsulated formats in all colorectal cell lines tested. Importantly, we also explored the in vivo impact of the drug combination on murine blood leukocytes, showing that the leukopenia induced by the free drugs could be significantly mitigated by nanoencapsulation. Taken together, this study demonstrates that formulating these agents within a single nanoparticle delivery platform may provide clinical utility beyond use as nonencapsulated agents.

Original languageEnglish
Pages (from-to)1246–1255
Number of pages10
JournalMolecular Pharmaceutics
Volume21
Issue number3
Early online date09 Feb 2024
DOIs
Publication statusPublished - 04 Mar 2024

Fingerprint

Dive into the research topics of 'Nanoencapsulation of MDM2 inhibitor RG7388 and class-I HDAC inhibitor entinostat enhances their therapeutic potential through synergistic antitumor effects and reduction of systemic toxicity'. Together they form a unique fingerprint.

Cite this